Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Pediatrics
Published in: World Journal of Pediatrics 1/2019

01-02-2019 | Original Article

Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database

Authors: Nanae Tanemura, Maika Asawa, Mayuko Kuroda, Tsuyoshi Sasaki, Yoshiaki Iwane, Hisashi Urushihara

Published in: World Journal of Pediatrics | Issue 1/2019

Login to get access

Abstract

Background

Off-label use of psychotropic prescriptions for pediatric patients has been increasing in Japan. This study sought to clarify pediatric patients’ off-label use of psychotropics approved only for adults in Japan.

Methods

This retrospective study on psychotropic utilization employed a pharmaceutical health insurance claims database supplied by a pharmacy for the fiscal year 2016. Seven psychotropic drugs were examined. For each drug, we calculated the proportion of patients aged < 16 years or who were under the approved age limit set in the United States out of all patients. The maximum daily dose of each drug within the study period was plotted by age.

Results

Data of 45,715 patients (female: 26,799, male: 18,916) with 331,920 prescriptions were examined in this study. For each drug, the proportion of pediatric patients aged < 16 years ranged from 0.15 to 1.1%, while the proportion of those under the approved age limit in the United States ranged from 0 to 0.27%. Olanzapine had the highest reported proportion. No drugs other than olanzapine were taken under the approved age limit in the United States.

Conclusions

We identified the pediatric off-label use of psychotropics that were limited to adult use in Japan. The results indicated the possibility of referring to international guidelines or evidence in clinical practice, but these factors do not discount the existing problems with off-label use. More clinical trials within the pediatric population in Japan are needed to address the issue of off-label use and obtain useful and reliable information in the package inserts for rational use in future pediatric patients.
Appendix
Available only for authorised users
Literature
1.
2.
Sekimizu M. PMDA’s challenges in pediatric drug development. Regul Sci Med Prod. 2015;5:159–66 (in Japanese).
3.
Nakagawa M. An unapproved and off-label use in circulatory area for pediatrics. Clin Psychiatry. 2016;79:863–9 (in Japanese).
4.
Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12:18–25.CrossRefPubMed
5.
Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, et al. Off-label use of drugs in children. Pediatrics. 2014;133:563–7.CrossRefPubMed
6.
Snyder KM, Reaman G, Avant D, Pazdur R. The impact of the written request process on drug development in childhood cancer. Pediatr Blood Cancer. 2013;60:531–7.CrossRefPubMed
7.
Nakamura T. Current status on pediatric drug development tagetted for neuropsychiatric disorder. Jpn J Child Adolescent Psychiatry. 2017;58:76–84 (in Japanese).
8.
Berdkan S, Rabbaa L, Hajj A, Eid B, Jabbour H, Osta NE, et al. Comparative assessment of off-label and unlicensed drug prescriptions in children: FDA versus ANSM guidelines. Clin Ther. 2016;38:1833–44.CrossRefPubMed
9.
Kuroki S, Seguchi Y, Miyashita S, Uramura K, Yamashita H, Kodaira M. Treatment guidelines for depression at puberty in British and North America. Jpn J Clin Psychiatry. 2011;40:1203–12 (in Japanese).
10.
Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914–5.CrossRefPubMed
11.
Hudgins JD, Bacho MA, Olsen KL, Bourgeois FT. Pediatric drug information available at the time of new drug approvals: a cross-sectional analysis. Pharmacoepidemiol Drug Saf. 2018;27:161–7.CrossRefPubMed
12.
Imoto M. Challenges to Unapproved Drugs. Egul Sci Med Prod. 2015;5:121–34 (in Japanese).
13.
Usami M, Iwadare Y, Kodaira M, Watanabe K, Saito K. Near infrared spectroscopy study of the frontopolar hemodynamic response and depressive mood in children with major depressive disorder: a pilot study. PLoS One. 2014;9:e86290.CrossRefPubMedPubMedCentral
14.
Ozaki M. Industries’ efforts in promoting pediatric drug development. Egul Sci Med Prod. 2015;5:151–8 (in Japanese).
15.
Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016;95:e3784.CrossRefPubMedPubMedCentral
16.
Kearns MA, Hawley KM. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists. J Psychiatr Pract. 2014;20:438–47.PubMedPubMedCentralCrossRef
17.
Czaja AS, Valuck R. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf. 2012;21:997–1004.CrossRefPubMed
18.
Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O. Off-label use of psychotropic medications in pediatric wards: a prospective study. Arch Pediatr. 2009;16:1252–60 (in French).CrossRefPubMed
19.
20.
Nakagome K. Actual condition survey on psychotropic prescription. Tokyo: Health Labour Sciences Research Grant; 2013.
21.
Okumura Y, Fujita J, Matsumoto T. Trends of psychotropic medication use among children and adolescents in Japan data from the national insurance claims database between 2002 and 2010. Seishin Shinkeigaku Zasshi. 2014;116:921–35 (in Japanese).PubMed
22.
23.
24.
Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry. 2000;9:147–61.CrossRefPubMed
25.
26.
Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, et al. Texas children’s medication algorithm project: update from texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:667–86.CrossRefPubMed
27.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMed
28.
Yamada K. Guideline on treatment for bipolar disorder. Jpn J Clin Psychopharmacol. 2017;20:541–7 (in Japanese).
29.
Miyata H, Ishii J. Psychopharmacology of antipsychotic drugs. J Pract Pharm. 2016;67:3186–92 (in Japanese).
30.
Akiyama K. Pharmacological profile of antipsychotic drug. Clin Psychiatry. 2002;44:238–43 (in Japanese).
31.
Usami M. Drug therapy with antidepressant in clinical psychiatry for child and adolescence. Jpn J Child Adolesc Psychiatry. 2017;58:146–56 (in Japanese).
32.
Saito T. Current status on clinical trials tagetted for pediatrics with psychotropic. Jpn J Clin Psychopharmacol. 2013;16:1731–9 (in Japanese).
33.
Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K. Genetic polymorphism of C452T (T127I) in Human γ-Glutamyl hydrolase in a Japanese population. Biol Pharm Bull. 2007;30:839–41.CrossRefPubMed
Metadata
Title
Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database
Authors
Nanae Tanemura
Maika Asawa
Mayuko Kuroda
Tsuyoshi Sasaki
Yoshiaki Iwane
Hisashi Urushihara
Publication date
01-02-2019
Publisher
Childrens Hospital, Zhejiang University School of Medicine
Published in
World Journal of Pediatrics / Issue 1/2019
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-018-0213-z

Other articles of this Issue 1/2019

World Journal of Pediatrics 1/2019 Go to the issue

Meta-analysis

Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn’s disease: a meta-analysis

Review Article

An update on the role of RANKL–RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases

Original Article

Transcutaneous bilirubin nomogram for evaluating the risk of hyperbilirubinemia in Iranian healthy newborns

Editorial

Early child development: a challenge in China

Original Article

Comparison of decision-making in neonatal care between China and Japan

Original Article

Characteristics and outcome of newborn admitted with acute bilirubin encephalopathy to a tertiary neonatal intensive care unit